Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Albumin batches and B19 parvovirus DNA

Albumin batches and B19 parvovirus DNA BACKGROUND: B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined. STUDY DESIGN AND METHODS: The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4‐ and 20‐percent albumin, respectively, from two different manufacturers. RESULTS: No B19 DNA was detected in the batches tested. CONCLUSION: The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Loading next page...
 
/lp/wiley/albumin-batches-and-b19-parvovirus-dna-pKEi1XTL0d

References (14)

Publisher
Wiley
Copyright
1995 AABB
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1995.35595259148.x
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined. STUDY DESIGN AND METHODS: The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4‐ and 20‐percent albumin, respectively, from two different manufacturers. RESULTS: No B19 DNA was detected in the batches tested. CONCLUSION: The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19.

Journal

TransfusionWiley

Published: May 1, 1995

There are no references for this article.